| Trial ID: | L1655 |
| Source ID: | NCT01593527
|
| Associated Drug: |
Acz885
|
| Title: |
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Acute Gouty Arthritis
|
| Interventions: |
DRUG: ACZ885|DRUG: Triamcinelone acetonide
|
| Outcome Measures: |
Primary: Proportion of patients experiencing new gouty arthritis flares during 12-week follow-up from dosing, 12 Weeks | Secondary: The time to the first new gout flare, 12 Weeks|Score on Visual Analog Scale at 72 hours to measure gouty arthritis pain intensity and resolution, 12 weeks|Number of patients needing rescue medication use during acute gouty arthritis flare(s), 12 Weeks|Measurement of efficacy using inflammatory markers, 12 Weeks|Time to 50% reduction of baseline pain intensity in the most affected joint, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2012-09
|
| Completion Date: |
2012-09
|
| Results First Posted: |
|
| Last Update Posted: |
2017-04-20
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01593527
|
